Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort

Brain, Behavior, & Immunity - Health

V. Barteau¹  I. Offerlin-Meyer²  Marion Leboyer²  Myrtille Andre³  J. Mallet³  F. Gabayet³  J.M. Dorey³  R.M. Honciuc³  Susana Barbosa³  M. Jarroir⁴  H. Yazbek⁴  M. Urbach⁴  K. Souryis⁵  Romain Rey⁶  Caroline Dubertret⁷  E. Haffen⁸  O. Godin⁸  G. Chesnoy-Servanin⁹  A. Vehier⁹  A. Szöke^1,10  Ophélia Godin^1,11  C. Portalier^1,11  R. Rey^1,11  D. Lacelle^1,11  Pierre Vidailhet^1,11  C. Roman^1,11  Caroline Barau^1,11  Bruno Aouizerate^1,11  Guillaume Fond^1,12  Emanuela Martinuzzi^1,12  Julien Dubreucq^1,13  I. Chéreau^1,14  Franck Schürhoff^1,14  Jasmina Mallet^1,15  Laetitia Davidovic^1,15  E. Vilà^1,16  S. Pires^1,16  B. Aouizerate^1,17  Ryad Tamouza^1,18  B. Pignon^1,18  Delphine Capdevielle^1,19  Fabrice Berna^1,19  Sylvain Leigner^2,20  F. Vaillant^2,21  C. Faget^2,21  C. Lançon^2,21  E. Metairie^2,21  P. Peri^2,21  D. Capdevielle^2,22  S. Esselin^2,22  C. Passerieux^2,22  A. Zinetti-Bertschy^2,23  G. Fond^2,23  L. Boyer^2,23  F. Berna^2,23  P. Vidailhet^2,23  Catherine Faget^2,24  Christine Passerieux^2,24  H. Laouamri^2,24  D. Misdrahi^2,24  Jean-Michel Dorey^2,24  Pierre-Michel Llorca^2,24  Mathieu Urbach^2,24  Nicolas Glaichenhaus^2,24  F. Schürhoff^2,24  M. Leboyer^2,24  S. Bensalem^2,24  O. Blanc^2,24  David Misdrahi^2,24  P.M. Llorca^2,24  Isabelle Chereau^2,24  Wahid Boukouaci^2,25  T. D'Amato^2,25  C. Dubertret^2,25  Marianne Foiselle^2,25  C. Fluttaz^2,25  H. Denizot^2,25  Baptiste Pignon^2,26  A. Deloge^2,26  Ching-Lien Wu^2,26  J. Dubreucq^2,26 

[1] AP-HM, Aix-Marseille Univ, School of Medicine - La Timone Medical Campus, EA 3279, CEReSS - Health Service Research and Quality of Life Center, Marseille, France;AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, service de Psychiatrie et Addictologie, Hopital Louis Mourier, Colombes, France;AP-HP, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de Psychiatrie et d’Addictologie (DMU IMPACT), Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), F-94010, France;AP-HP, INSERM U955, Translational Psychiatry Team, DHU Pe-PSY, Centre Expert Schizophrénie, Pôle de Psychiatrie et d’Addictologie des Hôpitaux Universitaires Henri Mondor, Paris Est University, 40 rue de Mesly, 94000, Créteil, France;APHP, Hôpital Henri Mondor, Plateforme de Ressources Biologiques, France;CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, EA 7280, Clermont-Ferrand, France;Centre Hospitalier Charles Perrens, Université de Bordeaux, Bordeaux, F-33076, France;Centre Référent de Réhabilitation Psychosociale et de Remédiation Cognitive (C3R), CH Alpes Isère, France;Corresponding author. Département Hospitalo-Universitaire de Psychiatrie, Hôpital Albert Chenevier, 40 rue de Mesly, Créteil, 94000, France.;Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France;Fondation FondaMental, France;Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France;INRAE, NutriNeuro, University of Bordeaux, U1286, Bordeaux, F-33076, France;INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier, France;Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France;Service Universitaire de psychiatrie et d'addictologie du Centre Hospitalier de Versailles, INSERM UMR1018, CESP, Team “DevPsy”, Université de Versailles Saint-Quentin-en-Yvelines, Paris, Saclay, France;University of Bordeaux, CNRS UMR 5287-INCIA « Neuroimagerie et cognition humaine », France;Université de Paris INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, France;AP-HP, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de Psychiatrie et d’Addictologie (DMU IMPACT), Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), F-94010, France;APHP, Hôpital Henri Mondor, Plateforme de Ressources Biologiques, France;FACE-SZ Clinical Coordinating Center (Fondation FondaMental), France;FACE-SZ Clinical Sites and Principal Collaborators in France, France;FACE-SZ Data Coordinating Center (Fondation FondaMental), France;Fondation FondaMental, France;Univ Paris Est Créteil, INSERM U955, IMRB, Translational NeuroPsychiatry Laboratory, F-94010, Créteil, France;Université Côte d’Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France;

关键词: Metabolic syndrome;    Schizophrenia;    Psychosis;    Inflammation;    Machine learning;    Precision medicine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Metabolic syndrome (MetS) is a highly prevalent and harmful medical disorder often comorbid with psychosis where it can contribute to cardiovascular complications. As immune dysfunction is a key shared component of both MetS and schizophrenia (SZ), this study investigated the relationship between immune alterations and MetS in patients with SZ, whilst controlling the impact of confounding clinical characteristics including psychiatric symptoms and comorbidities, history of childhood maltreatment and psychotropic treatments. Method: A total of 310 patients meeting DSM-IV criteria for SZ or schizoaffective disorders (SZA), with or without MetS, were systematically assessed and included in the FondaMental Advanced Centers of Expertise for Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients, including psychotic symptomatology, psychiatric comorbidities and history of childhood maltreatment were recorded and the serum levels of 18 cytokines were measured. A penalized regression method was performed to analyze associations between inflammation and MetS, whilst controlling for confounding factors. Results: Of the total sample, 25% of patients had MetS. Eight cytokines were above the lower limit of detection (LLOD) in more than 90% of the samples and retained in downstream analysis. Using a conservative Variable Inclusion Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6, IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α were associated with MetS. As for clinical variables, age, sex, body mass index (BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP), alcohol abuse, current tobacco smoking, and treatment with antidepressants and anxiolytics were all associated with MetS. Conclusion: We have identified five cytokines associated with MetS in SZ suggesting that patients with psychotic disorders and MetS are characterized by a specific “immuno-metabolic” profile. This may help to design tailored treatments for this subgroup of patients with both psychotic disorders and MetS, taking one more step towards precision medicine in psychiatry.

【 授权许可】

Unknown